1595 related articles for article (PubMed ID: 12937899)
41. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
[TBL] [Abstract][Full Text] [Related]
42. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
43. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
44. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
Lou Y; Wang G; Lizée G; Kim GJ; Finkelstein SE; Feng C; Restifo NP; Hwu P
Cancer Res; 2004 Sep; 64(18):6783-90. PubMed ID: 15374997
[TBL] [Abstract][Full Text] [Related]
45. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
46. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
47. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
Hawkins WG; Gold JS; Dyall R; Wolchok JD; Hoos A; Bowne WB; Srinivasan R; Houghton AN; Lewis JJ
Surgery; 2000 Aug; 128(2):273-80. PubMed ID: 10923004
[TBL] [Abstract][Full Text] [Related]
48. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro.
Vujanovic L; Ranieri E; Gambotto A; Olson WC; Kirkwood JM; Storkus WJ
Cancer Gene Ther; 2006 Aug; 13(8):798-805. PubMed ID: 16645618
[TBL] [Abstract][Full Text] [Related]
49. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
Johnson TS; Mahnke K; Storn V; Schönfeld K; Ring S; Nettelbeck DM; Haisma HJ; Le Gall F; Kontermann RE; Enk AH
Clin Cancer Res; 2008 Dec; 14(24):8169-77. PubMed ID: 19088032
[TBL] [Abstract][Full Text] [Related]
51. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
52. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
53. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
54. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
55. A high-affinity T-helper epitope enhances peptide-pulsed dendritic cell-based vaccine.
Li A; Xiong S; Lin Y; Liu R; Chu Y
DNA Cell Biol; 2011 Nov; 30(11):883-92. PubMed ID: 21612399
[TBL] [Abstract][Full Text] [Related]
56. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
57. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
58. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
59. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
60. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
